Lupin Limited is a transnational pharmaceutical company that focuses on the production and marketing of a diverse range of generic and branded formulations, as well as active pharmaceutical ingredients (APIs). The company is recognized for its significant presence in various therapeutic areas, including Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastrointestinal, and Anti-Infectives. Lupin holds a leading position in the global market for Anti-TB and Cephalosporins. Additionally, it is engaged in the development of specialty products with a robust pipeline in high-barrier markets, including Inhalation, Biosimilars, and Complex Injectables. The majority of Lupin’s sales are generated from the United States, highlighting its strong international footprint in the pharmaceutical sector.
Executive Director, Global CFO and Head Corporate Affairs
11 past transactions
Eli Lilly - Huminsulin Business
Acquisition in 2024
Eli Lilly - Huminsulin Business is a unit of Eli Lilly that provides healthcare services including diabetes, effectively reducing blood sugar levels in adults and children.
Medisol
Acquisition in 2023
Medisol is a French pharmaceutical firm situated in Lyon that specializes in generic injectable pharmaceuticals manufactured in France using chemicals and materials supplied in France and the European Union. The Medisol product line is offered to hospitals and retail pharmacies throughout France.
Southern Cross Pharma
Acquisition in 2021
Southern Cross Pharma is a privately owned pharmaceutical company that operates in the Australian and New Zealand markets. The company specializes in the development, registration, and distribution of generic pharmaceutical products. Its primary focus is on supplying prescription medications to retail pharmacies while also directly marketing its own-brand products, known as SXP, to hospitals. This dual approach allows Southern Cross Pharma to efficiently meet the demands of its clients, ensuring a reliable supply of medications to end consumers.
Symbiomix Therapeutics
Acquisition in 2017
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.
Temmler Werke
Acquisition in 2015
The Temmler Group, with its 7 production sites in Europe, is one of the largest providers of contract services in the pharmaceutical environment. Temmler has a wide experience in formulation development of finished solid, semi-solid and liquid dosage forms, in manufacture, packaging, blinding, distribution and return handling of clinical trial supplies, in the optimization of established manufacturing processes as well as in the contract manufacture of medicinal products with marketing authorization, supplemented by Quality Control and Analytical services. Temmler offers services from stand-alone processes according to customer specifications, to strategic services comprising the entire supply chain.
Novel Laboratories
Acquisition in 2015
Novel Laboratories, Inc. is a pharmaceutical company focused on the research, development, and manufacturing of both generic and branded products across various therapeutic classes. The company offers a diverse product portfolio that includes immediate and modified release tablets, capsules, powders, and liquids such as solutions and suspensions. Additionally, they produce topical products like gels, lotions, foams, ointments, and creams, along with respiratory products, vaginal and rectal suppositories, and otic solutions. Novel Laboratories also specializes in injectables, which include lyophilized powders and solutions in various formats, as well as ophthalmic solutions and suspensions. Through its comprehensive range of dosage forms, the company aims to meet the evolving needs of the pharmaceutical market.
GAVIS Pharmaceuticals
Acquisition in 2015
GAVIS Pharmaceuticals, LLC is a pharmaceutical manufacturer based in Franklin Township, New Jersey, specializing in the sales and distribution of niche drug products. The company offers a diverse range of pharmaceutical formulations, including analgesics, gastric anti-inflammatories, antidepressants, and antifungal medications. GAVIS focuses on providing effective healthcare solutions through its targeted product offerings in the pharmaceutical market.
JSC Biocom
Acquisition in 2015
JSC Biocom is a pharmaceutical company based in Stavropol, Russian Federation, founded in 1991. The company specializes in the production of generic pharmaceutical products, primarily in tablet and capsule forms. Its product range includes agents that target various health systems, such as the hemopoietic and cardiovascular systems, the alimentary system, the nervous system, and the musculoskeletal system, along with dermatological and antimicrobial agents. In addition to its own product offerings, JSC Biocom provides pharmaceutical contract manufacturing services. As of July 2015, the company operates as a subsidiary of Lupin Limited.
Medquímica Indústria Farmacêutica
Acquisition in 2015
Medquímica Indústria Farmacêutica S.A. is a Brazilian pharmaceutical company established in 1975, headquartered in Juiz de Fora, Brazil. The company specializes in developing a wide range of solid and liquid medications, including over-the-counter drugs, generics, and dietary supplements. Medquímica's product offerings also encompass categories such as cardiology, gastroenterology, and hospital pharmaceuticals. The company serves its customers through a network of representatives across Brazil, ensuring broad access to its diverse healthcare solutions. As of May 2015, Medquímica operates as a subsidiary of Lupin Limited.
Pharma Dynamics
Acquisition in 2015
Pharma Dynamics (Pty) Ltd. is a pharmaceutical company based in Cape Town, South Africa, founded in 2001. The company specializes in providing a wide range of generic pharmaceuticals and offers products across various therapeutic categories, including cardiovascular, central nervous system, and pediatric care. Additionally, Pharma Dynamics supplies over-the-counter medications for conditions such as cold and flu, allergies, heartburn, and immune support. The company also focuses on critical hospital products, which include antibiotics and specialty healthcare solutions for both male and female patients. Pharma Dynamics primarily serves the South African market and operates as a subsidiary of Lupin Limited.
Laboratorios Grin
Acquisition in 2014
Laboratorios Grin is a pharmaceutical company that manufactures ophthalmological products, antivertiginosis, and oral antibiotics products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.